By participating in this confidential and anonymous study, participants are granted access to the finalised in-depth report, with an anticipated release Autumn 2022. The report will reveal key trends and grant actionable insights for both board and executive level participants on a personal career level but also importantly enable application to their organisations.
PIR International’s 2022 Biotech Board & Executive Remuneration Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in this sector.
All data is collected in the strictest confidence and is subject to EU/UK GDPR regulations.